{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:56:57Z","timestamp":1790805417708,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hydrocodone and oxycodone are widely used for acute postoperative pain and are metabolized by CYP2D6 to more potent agonists. The clinical impact of CYP2D6 metabolizer status on hydrocodone and oxycodone analgesic response remains uncertain. This secondary analysis of A Depression and Opioid Pragmatic Trial in Pharmacogenetics (ADOPT PGx) evaluated associations between CYP2D6 phenotype and postoperative pain and opioid consumption among patients taking hydrocodone or oxycodone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This analysis included participants from the ADOPT PGx Acute Pain Trial (NCT05966129). Among patients who consumed hydrocodone or oxycodone postoperatively, analyses were conducted separately by drug, comparing outcomes between poor (PM) vs. normal (NM) and intermediate (IM) vs. normal CYP2D6 metabolizers, with phenotypes predicted by genotype and concomitant CYP2D6 inhibitor use. A positive control analysis was performed among tramadol users. Outcomes were cumulative opioid use (morphine milligram equivalents) and composite Patient-Reported Outcomes Measurement Information System\u00ae pain intensity scores at 10 days post-surgery. Regression models adjusted for demographics, surgery type, trial site, and non-opioid analgesic use;\n                      <jats:italic>P<\/jats:italic>\n                      -values were corrected for multiple comparisons.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort primarily underwent orthopedic procedures and concomitant non-opioid analgesic use was common across hydrocodone, oxycodone, and tramadol cohorts, with 88%\u2013100% of patients receiving at least one non-opioid analgesic or nerve block. Among hydrocodone users, predicted CYP2D6 phenotype was not associated with postoperative hydrocodone consumption (PM vs. NM: mean ratio [MR] = 1.12, 95% CI 0.92\u20131.36,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.262) or pain intensity (PM vs. NM: odds ratio [OR] = 1.13, 95% CI 0.66\u20131.92,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.668). Among oxycodone users, CYP2D6 phenotype was not associated with postoperative oxycodone consumption (PM vs. NM: MR = 1.02, 95% CI 0.79\u20131.34,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.880) or pain intensity (PM vs. NM: OR = 0.84, 95% CI 0.47\u20131.51,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.568). Similarly, in the positive control tramadol cohort, CYP2D6 phenotype was not associated with tramadol consumption (PM vs. NM: MR = 1.02, 95% CI 0.79\u20131.32,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.847) or pain intensity (PM vs. NM: OR = 1.43, 95% CI 0.66\u20133.00,\n                      <jats:italic>P<\/jats:italic>\n                      = 0.668).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Predicted CYP2D6 metabolizer status was not associated with postoperative pain control or opioid use in patients taking hydrocodone, oxycodone, or positive-control tramadol, suggesting that multimodal analgesic use may have weakened pharmacogenetic effects. These findings suggest that CYP2D6 phenotype associations with hydrocodone or oxycodone analgesic response, if present, are attenuated in multimodal postoperative pain management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1817652","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:06:13Z","timestamp":1778486773000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["CYP2D6 phenotype and post-surgical pain control with hydrocodone and oxycodone"],"prefix":"10.3389","volume":"17","author":[{"given":"Christelle","family":"Lteif","sequence":"first","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel A.","family":"Myers","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica N.","family":"Elwood","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth C.","family":"Harris","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hrishikesh","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Duke Clinical Research Institute, Duke University School of Medicine","place":["Durham, NC, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul R.","family":"Dexter","sequence":"additional","affiliation":[{"name":"School of Medicine, Indiana University","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josh F.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Departments of Biomedical Informatics and Medicine, Vanderbilt University Medical Center","place":["Nashville, TN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renee","family":"Rider","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, National Human Genome Research Institute","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Skaar","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Indiana University School of Medicine","place":["Indianapolis, IN, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Volpi","sequence":"additional","affiliation":[{"name":"Division of Genomic Medicine, National Human Genome Research Institute","place":["Bethesda, MD, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida","place":["Gainesville, FL, United States"]},{"name":"Clinical and Translational Science Institute, The Ohio State University","place":["Columbus, OH, United States"]},{"name":"Department of Internal Medicine, The Ohio State University College of Medicine","place":["Columbus, OH, United States"]},{"name":"Department of Pharmaceutics and Pharmacology, The Ohio State University College of Pharmacy","place":["Columbus, OH, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio D.","family":"Duarte","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa H.","family":"Cavallari","sequence":"additional","affiliation":[{"name":"Department of Pharmacotherapy and Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy, University of Florida","place":["Gainesville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"e1113","DOI":"10.1097\/PR9.0000000000001113","article-title":"Effects of pharmacogenetic profiles on pediatric pain relief and adverse events with ibuprofen and oxycodone","volume":"8","author":"Ali","year":"2023","journal-title":"Pain Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"669","DOI":"10.2217\/pgs.09.13","article-title":"Variation in the COMT gene: implications for pain perception and pain treatment","volume":"10","author":"Andersen","year":"2009","journal-title":"Pharmacogenomics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00228-011-1093-5","article-title":"Do CYP2D6 genotypes reflect oxycodone requirements for cancer patients treated for cancer pain? A cross-sectional multicentre study","volume":"68","author":"Andreassen","year":"2012","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2217\/pgs-2016-0183","article-title":"CYP2D6 pharmacogenetic and oxycodone pharmacokinetic association study in pediatric surgical patients","volume":"18","author":"Balyan","year":"2017","journal-title":"Pharmacogenomics"},{"key":"B5","doi-asserted-by":"publisher","first-page":"102905","DOI":"10.1016\/j.japh.2025.102905","article-title":"Evaluation of the impact of CYP2D6 testing on outcomes in patients taking opioids","volume":"2025","author":"Brady","year":"2003","journal-title":"J. Am. Pharm. Assoc."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1111\/cts.13376","article-title":"Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigators","volume":"15","author":"Cavallari","year":"2022","journal-title":"Clin. Transl. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e2558299","DOI":"10.1001\/jamanetworkopen.2025.58299","article-title":"CYP2D6-Guided opioid management and postoperative pain control: a randomized clinical trial","volume":"9","author":"Cavallari","year":"2026","journal-title":"JAMA Netw. Open"},{"key":"B8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1124\/jpet.123.001651","article-title":"Hydrocodone, oxycodone, and morphine metabolism and drug-drug interactions","volume":"387","author":"Coates","year":"2023","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/cpt.2149","article-title":"Clinical pharmacogenetics implementation consortium guideline for CYP2D6, OPRM1, and COMT genotypes and select opioid therapy","volume":"110","author":"Crews","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"B10","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s00228-015-1857-4","article-title":"Effect of the CYP2D6 gene polymorphism on postoperative analgesia of tramadol in Han nationality nephrectomy patients","volume":"71","author":"Dong","year":"2015","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1007\/s00167-013-2750-2","article-title":"Pain after knee arthroplasty: an unresolved issue","volume":"22","author":"Grosu","year":"2014","journal-title":"Knee Surg. Sports Traumatol. Arthrosc."},{"key":"B12","unstructured":"PROMIS \u2013 pain intensity: scoring manual\n          \n          \n          2021"},{"key":"B13","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1248\/bpb.b23-00030","article-title":"Decreased analgesic effect of tramadol in Japanese patients with CYP2D6 intermediate metabolizers after orthopedic surgery","volume":"46","author":"Kamiya","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"B14","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.cca.2021.08.004","article-title":"Endogenous and iatrogenic sources of variability in response to opioid therapy in post-surgical and injured orthopedic patients","volume":"522","author":"Langman","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"B15","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1097\/EJA.0000000000001691","article-title":"Pain management after total knee arthroplasty: PROcedure SPEcific postoperative pain ManagemenT recommendations","volume":"39","author":"Lavand'homme","year":"2022","journal-title":"Eur. J. Anaesthesiol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1002\/cpt.3314","article-title":"Use of CYP2D6 inhibitors with CYP2D6 opioids: association with emergency department visits for pain","volume":"116","author":"Nahid","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e2523543","DOI":"10.1001\/jamanetworkopen.2025.23543","article-title":"CYP2D6 phenotypes and emergency department visits among patients receiving opioid treatment","volume":"8","author":"Nahid","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"B18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/clpt.2010.279","article-title":"CPIC: clinical pharmacogenetics implementation consortium of the pharmacogenomics research network","volume":"89","author":"Relling","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"key":"B19","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/cpt.1651","article-title":"The clinical pharmacogenetics implementation consortium: 10 years later","volume":"107","author":"Relling","year":"2020","journal-title":"Clin. Pharmacol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1842","DOI":"10.1038\/s41436-018-0431-8","article-title":"CYP2D6-guided opioid therapy improves pain control in CYP2D6 intermediate and poor metabolizers: a pragmatic clinical trial","volume":"21","author":"Smith","year":"2019","journal-title":"Genet. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.2147\/PGPM.S136341","article-title":"CYP2D6 phenotypes are associated with adverse outcomes related to opioid medications","volume":"10","author":"St","year":"2017","journal-title":"Pharmgenomics Pers. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"e2125","DOI":"10.1097\/GOX.0000000000002125","article-title":"American society of plastic surgeons member post-operative opioid prescribing patterns","volume":"7","author":"Torabi","year":"2019","journal-title":"Plast. Reconstr. Surg. Glob. Open"},{"key":"B23","unstructured":"Drug development and drug interactions: table of substrates, inhibitors and inducers\n          \n          \n          2023"},{"key":"B24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1080\/14622416.2024.2430161","article-title":"Do CYP2D6 genotypes affect oxycodone dose, pharmacokinetics, pain, and adverse effects in cancer?","volume":"25","author":"Wong","year":"2024","journal-title":"Pharmacogenomics"},{"key":"B25","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1302\/2058-5241.3.180004","article-title":"Chronic pain after total knee arthroplasty","volume":"3","author":"Wylde","year":"2018","journal-title":"EFORT Open Rev."},{"key":"B26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41397-021-00253-5","article-title":"Impact of genetic variation in CYP2C19, CYP2D6, and CYP3A4 on oxycodone and its metabolites in a large database of clinical urine drug tests","volume":"22","author":"Zhu","year":"2022","journal-title":"Pharmacogenomics J."},{"key":"B27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/j.1399-6576.2009.02104.x","article-title":"Impact of the CYP2D6 genotype on post-operative intravenous oxycodone analgesia","volume":"54","author":"Zwisler","year":"2010","journal-title":"Acta Anaesthesiol. Scand."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1817652\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T08:06:18Z","timestamp":1778486778000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1817652\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,11]]},"references-count":27,"alternative-id":["10.3389\/fphar.2026.1817652"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1817652","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,11]]},"article-number":"1817652"}}